Bioactives in Overweight and Obesity


Vijay Kumar Sehgal


No Abstract.


How to Cite
Sehgal, V. K. (2016). Bioactives in Overweight and Obesity. International Journal of Medical and Dental Sciences, 1114–1115.


  1. Critical Reviews in Food Science and Nutrition 2013; 53:929-42.
  2. Padwal R, Li SK, Lau DC. Long-term pharmacocapsule for obesity and overweight. Cochrane Database Syst Rev(3):CD004094.
  3. Weir MA, Beyea MM, Gomes T Juuurlink DN, Mamdani M, Blake PG, Wald R, Garg AX. Orlistat and acute kidney injury: an analysis of 953 patients. Arch Intern Med 2011; 171(7):703-4.
  4. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, et al. Effect of Sibutramine on cardiovascular outcomes in overweight and obese subjects. New England Journal of Medicine 2010; 363(10):905-17.
  5. Torgerson JS, Hauptman J, Boldrin MN. Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27(1):15561.
  6. Torres-Fuentes C, Schellens H, Dinen TG, Cryan GF. A natural solution for obesity: bioactives for the prevention and treatment of weight gain. A review: Nutritional Neurosciences 2015 Feb; 18(2):49-65.
  7. Boschmann M, Thielecke F. The effects of epigallocatechin-3-gallate on thermogenesis and fat oxidation in obese men: a pilot study. J. Am Coll Nutr 2007; 26(4):389S-95S.

Most read articles by the same author(s)